BioAgenda has allocated seed funding to launch a major white paper analysis of the successes and failures of the biotech business model. The study is titled: BIOTECH AT 35: A COMPREHENSIVE REPORT ON THE SUCCESSES AND FAILURES OF BIOTECHNOLOGY, AND A BLUE-RIBBON COMMISSION’S PROPOSALS FOR REFORM. Authors include BioAgenda principals and outside experts. BioAgenda is assembling a blue-ribbon commission that includes all stakeholders, including leaders from industry, investment and banking, science, academia, patient groups, critics, and public policy. BioAgenda is seeking additional funding for the study. For a summary of the study click here.